Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: previous (489), earlier (173), prior (757), former (618), past (217), above (874)

University Hospital Southampton NHS Foundation Trust Constitution

Description: Read our constitution here.
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/University-Hospital-Southampton-NHS-Foundation-Trust-Constitution.pdf

Papers Council of Governors 20 July 2022

Description: Agenda attachments 1 CoG Agenda - 20.07.2022.docx Date Time Location Chair Agenda Council of Governors 20/07/2022 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-20-July-2022.pdf

UHS ICE Download manual

Description: User manual for UHS ICE Download service
Url: /Media/UHS-website-2019/Docs/Services/Pathology/ICE/UHS-ICE-Download-manual.pdf

Cytarabine_2000_FludarabineIdarubicin_FLA-Ida

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (2000)-FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cytarabine (2000
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine-2000-FludarabineIdarubicin-FLA-Ida.pdf

Cytarabine_1000_FludarabineIdarubicin_FLA-Ida

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (1000)-FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cytarabine (1000
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine-1000-FludarabineIdarubicin-FLA-Ida.pdf

Tisacel-Cytarabine (500)-Etoposide (150)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE (500) – ETOPOSIDE (150) Regimen This regimen will only be available to prescribe at the Wessex Blood
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen This regimen will only be available to prescribe at
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

Tisacel-Bendamustine(90)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – BENDAMUSTINE (90) Regimen This regimen will only be available to prescribe at the Wessex Blood and Ma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Bendamustine90.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

Vulnerable with capacity

Description: Are there situations where a capacitous patient is nonetheless vulnerable to adverse decision making?
Url: /HealthProfessionals/Clinical-law-updates/Vulnerable-with-capacity.aspx

1 to 10 of 28

Previous 1 2 3 Next